A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

127

Enrollment

INDUSTRY

Sponsor class

Stopped After review of data which showed low likelihood of efficacy in these patients Novartis decided to terminate the trial early. Termination was not safety related

Conditions

Non-small Cell Lung Cancer (NSCLC)
Triple Negative Breast Cancer (TNBC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer Microsatellite Stable (MSS)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

OTHER: NZV930
OTHER: PDR001
DRUG: NIR178

Sponsor

Novartis Pharmaceuticals